Biology
5th Edition
ISBN: 9781260487947
Author: BROOKER
Publisher: MCG
expand_more
expand_more
format_list_bulleted
Concept explainers
Videos
Question
Chapter 21.2, Problem 3CC
Summary Introduction
To explain: The way in which sgRNA is different from certain components of the bacterial defense system.
Introduction: CRISPR-Cas system is a system used by the bacterial defense mechanism. However, this system can be used to modify the genes. This method of using a CRISPR-Cas system to alter the genes in an organism is known as CRISPR-Cas technology. sgRNA stands for “single guide RNA”. It is used in CRISPR-Cas technology. sgRNA is produced in such a way that it is complementary to the target gene. Therefore, it becomes easy for the researchers to locate the target gene from the complete DNA strand.
Expert Solution & Answer
Want to see the full answer?
Check out a sample textbook solution
Students have asked these similar questions
elect molecular outcomes that can be achieved with the CRISPR-Cas9 system (Check all that apply.)
Gene activation
Gene repression
Loss of gene function
Creation of a targeted mutation within a gene
Creation of many copies of a specific gene
Define recognition site. Using examples to support your answer,depict the palindromic nature of recognition sites.
List and briefly describe four types of molecules that can bind to an ncRNA.
Chapter 21 Solutions
Biology
Ch. 21.1 - Prob. 1CSCh. 21.1 - Prob. 1CCCh. 21.1 - Prob. 2CCCh. 21.1 - Prob. 3CCCh. 21.2 - Prob. 1CCCh. 21.2 - Prob. 2CCCh. 21.2 - Prob. 3CCCh. 21.3 - Prob. 1EQCh. 21.3 - Prob. 2EQCh. 21.3 - Prob. 3EQ
Ch. 21.4 - Prob. 1CCCh. 21.4 - Prob. 1CSCh. 21.5 - Prob. 1CSCh. 21.5 - Repetitive Sequences and Transposable Elements...Ch. 21 - Prob. 1TYCh. 21 - DNA ligase is needed in a cloning experiment a. to...Ch. 21 - Prob. 3TYCh. 21 - Why is Taq polymerase used in PCR rather than...Ch. 21 - Lets suppose you want to clone a gene that has...Ch. 21 - In the CRISPR-Cas technology for editing genes,...Ch. 21 - Prob. 7TYCh. 21 - The enzyme that helps short segments of DNA move...Ch. 21 - Prob. 9TYCh. 21 - Which of the following was not a goal of the Human...Ch. 21 - Prob. 1CQCh. 21 - Briefly describe whether or not each of the...Ch. 21 - Prob. 3CQCh. 21 - Identify and discuss three important advances that...Ch. 21 - Prob. 2COQ
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.Similar questions
- The Adaptive Immune Response Is a Specific Defense Against Infection Researchers have been having a difficult time developing a vaccine against a certain pathogenic virus as a result of the lack of a weakened strain. They turn to you because of your wide knowledge of recombinant DNA technology and the immune system. How could you vaccinate someone against the virus, using a cloned gene from the virus that encodes a cell-surface protein?arrow_forwardAnalyzing Cloned Sequences What kind of information can a DNA sequence provide to a researcher studying a disease-causing gene?arrow_forwardMicroRNAs (miRNAs) ____________________. (select all that apply) Group of answer choices are produced from a precursor miRNA transcript. Are solely derived from double-stranded RNA viruses control gene expression by base-pairing with DNA sequences can degrade RNAs by using their intrinsic catalytic activityarrow_forward
- Compare and contrast the roles of crRNA and tracrRNA in the defense process against bacteriophages provided by the CRISPRCas system.arrow_forwardGive typing answer with explanation and conclusion lets say, you treat a bacteria with an unknown antibiotic. After three short days, the bacteria becomes resistant to the antibiotic. Mind you, after three days you measure the S12 protein mutations and they highly increased those three days. what is most likey the antibiotic identity and why?arrow_forwardCompare and contrast anti-miRNA oligonucleotides, locked nucleicacids (LNAs), and antagomirs, which may eventually be used to treat certain forms of cancer.arrow_forward
- determine the cytokine the sequence template what is cytokine accession number at GenBank ?arrow_forwardExplain Sigma factor recognition sequences?arrow_forwardWho Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?arrow_forward
- Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?arrow_forwardThe Adaptive Immune Response Is a Specific Defense Against Infection In cystic fibrosis gene therapy, scientists propose the use of viral vectors to deliver normal genes to cells in the lungs. What immunological risks are involved in this procedure?arrow_forwardmiRNA molecules act as specificity factors, which direct effector proteins to target ______ molecules via base-pairing. A. RNA B. Carbohydrate C. Lipid D. DNA E. Proteinarrow_forward
arrow_back_ios
SEE MORE QUESTIONS
arrow_forward_ios
Recommended textbooks for you
Human Heredity: Principles and Issues (MindTap Co...BiologyISBN:9781305251052Author:Michael CummingsPublisher:Cengage Learning
Biology (MindTap Course List)BiologyISBN:9781337392938Author:Eldra Solomon, Charles Martin, Diana W. Martin, Linda R. BergPublisher:Cengage Learning
Human Heredity: Principles and Issues (MindTap Co...
Biology
ISBN:9781305251052
Author:Michael Cummings
Publisher:Cengage Learning
Biology (MindTap Course List)
Biology
ISBN:9781337392938
Author:Eldra Solomon, Charles Martin, Diana W. Martin, Linda R. Berg
Publisher:Cengage Learning
QCE Biology: Introduction to Gene Expression; Author: Atomi;https://www.youtube.com/watch?v=a7hydUtCIJk;License: Standard YouTube License, CC-BY